Great Point Partners LLC trimmed its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 63.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 275,000 shares of the company's stock after selling 482,929 shares during the quarter. Dianthus Therapeutics makes up 2.2% of Great Point Partners LLC's portfolio, making the stock its 18th biggest position. Great Point Partners LLC owned 0.93% of Dianthus Therapeutics worth $7,530,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DNTH. Quest Partners LLC raised its position in shares of Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company's stock valued at $31,000 after acquiring an additional 1,124 shares during the period. SG Americas Securities LLC acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at $112,000. American Century Companies Inc. increased its position in shares of Dianthus Therapeutics by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company's stock valued at $788,000 after buying an additional 8,473 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in Dianthus Therapeutics during the 2nd quarter worth $236,000. Finally, WINTON GROUP Ltd bought a new position in Dianthus Therapeutics during the second quarter worth about $265,000. 47.53% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of research firms have issued reports on DNTH. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Wedbush lowered their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating for the company in a research note on Friday, August 9th. Oppenheimer lifted their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, November 11th. Finally, Raymond James raised their price objective on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an "outperform" rating in a report on Friday, November 8th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $46.43.
Get Our Latest Analysis on Dianthus Therapeutics
Dianthus Therapeutics Stock Performance
Shares of NASDAQ DNTH opened at $23.86 on Wednesday. The stock has a market capitalization of $706.18 million, a PE ratio of -9.54 and a beta of 1.84. Dianthus Therapeutics, Inc. has a 52 week low of $6.58 and a 52 week high of $33.77. The stock has a 50 day moving average price of $26.91 and a 200 day moving average price of $26.61.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.
Dianthus Therapeutics Profile
(
Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
